As the global economy mends, the 2021 growth of Oculopharyngeal Muscular Dystrophy (OPMD) will have significant change from previous year. According to our (Publisher) latest study, the global Oculopharyngeal Muscular Dystrophy (OPMD) market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Oculopharyngeal Muscular Dystrophy (OPMD) market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States Oculopharyngeal Muscular Dystrophy (OPMD) market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Oculopharyngeal Muscular Dystrophy (OPMD) market, reaching US$ million by the year 2028. As for the Europe Oculopharyngeal Muscular Dystrophy (OPMD) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Oculopharyngeal Muscular Dystrophy (OPMD) players cover Benitec Biopharma Inc., Bioblast Pharma, BioMarin, and PTC Therapeutics, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Oculopharyngeal Muscular Dystrophy (OPMD) market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Tablets
Capsules
Injectable
Other
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Benitec Biopharma Inc.
Bioblast Pharma
BioMarin
PTC Therapeutics
NS Pharma
Nobelpharma Co., Ltd
Santhera Pharmaceuticals
Pfizer Inc.
Marathon Pharmaceuticals
Fibrogen
Bristol-Myers Squibb
Sarepta Therapeutics
GSK
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Oculopharyngeal Muscular Dystrophy (OPMD) by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Oculopharyngeal Muscular Dystrophy (OPMD) by Country/Region, 2017, 2022 & 2028
2.2 Oculopharyngeal Muscular Dystrophy (OPMD) Segment By Type
2.2.1 Tablets
2.2.2 Capsules
2.2.3 Injectable
2.2.4 Other
2.3 Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type
2.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2022)
2.3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue and Market Share By Type (2017-2022)
2.3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price By Type (2017-2022)
2.4 Oculopharyngeal Muscular Dystrophy (OPMD) Segment By Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application
2.5.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Market Share By Application (2017-2022)
2.5.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue and Market Share By Application (2017-2022)
2.5.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price By Application (2017-2022)
3 Global Oculopharyngeal Muscular Dystrophy (OPMD) by Company
3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Breakdown Data by Company
3.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales by Company (2020-2022)
3.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Company (2020-2022)
3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue by Company (2020-2022)
3.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Company (2020-2022)
3.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Company (2020-2022)
3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Company
3.4 Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Location Distribution
3.4.2 Players Oculopharyngeal Muscular Dystrophy (OPMD) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Oculopharyngeal Muscular Dystrophy (OPMD) by Geographic Region
4.1 World Historic Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Geographic Region (2017-2022)
4.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue by Geographic Region
4.2 World Historic Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country/Region (2017-2022)
4.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales by Country/Region (2017-2022)
4.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue by Country/Region
4.3 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
4.4 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
4.5 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
4.6 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth
5 Americas
5.1 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country
5.1.1 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022)
5.1.2 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022)
5.2 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type
5.3 Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region
6.1.1 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2017-2022)
6.1.2 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2017-2022)
6.2 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type
6.3 APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) by Country
7.1.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022)
7.1.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022)
7.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type
7.3 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) by Country
8.1.1 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022)
8.1.2 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022)
8.2 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type
8.3 Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oculopharyngeal Muscular Dystrophy (OPMD)
10.3 Manufacturing Process Analysis of Oculopharyngeal Muscular Dystrophy (OPMD)
10.4 Industry Chain Structure of Oculopharyngeal Muscular Dystrophy (OPMD)
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors
11.3 Oculopharyngeal Muscular Dystrophy (OPMD) Customer
12 World Forecast Review for Oculopharyngeal Muscular Dystrophy (OPMD) by Geographic Region
12.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Forecast by Region
12.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecast by Region (2023-2028)
12.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecast By Type
12.7 Global Oculopharyngeal Muscular Dystrophy (OPMD) Forecast By Application
13 Key Players Analysis
13.1 Benitec Biopharma Inc.
13.1.1 Benitec Biopharma Inc. Company Information
13.1.2 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Benitec Biopharma Inc. Main Business Overview
13.1.5 Benitec Biopharma Inc. Latest Developments
13.2 Bioblast Pharma
13.2.1 Bioblast Pharma Company Information
13.2.2 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Bioblast Pharma Main Business Overview
13.2.5 Bioblast Pharma Latest Developments
13.3 BioMarin
13.3.1 BioMarin Company Information
13.3.2 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 BioMarin Main Business Overview
13.3.5 BioMarin Latest Developments
13.4 PTC Therapeutics
13.4.1 PTC Therapeutics Company Information
13.4.2 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 PTC Therapeutics Main Business Overview
13.4.5 PTC Therapeutics Latest Developments
13.5 NS Pharma
13.5.1 NS Pharma Company Information
13.5.2 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 NS Pharma Main Business Overview
13.5.5 NS Pharma Latest Developments
13.6 Nobelpharma Co., Ltd
13.6.1 Nobelpharma Co., Ltd Company Information
13.6.2 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Nobelpharma Co., Ltd Main Business Overview
13.6.5 Nobelpharma Co., Ltd Latest Developments
13.7 Santhera Pharmaceuticals
13.7.1 Santhera Pharmaceuticals Company Information
13.7.2 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.7.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Santhera Pharmaceuticals Main Business Overview
13.7.5 Santhera Pharmaceuticals Latest Developments
13.8 Pfizer Inc.
13.8.1 Pfizer Inc. Company Information
13.8.2 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Pfizer Inc. Main Business Overview
13.8.5 Pfizer Inc. Latest Developments
13.9 Marathon Pharmaceuticals
13.9.1 Marathon Pharmaceuticals Company Information
13.9.2 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Marathon Pharmaceuticals Main Business Overview
13.9.5 Marathon Pharmaceuticals Latest Developments
13.10 Fibrogen
13.10.1 Fibrogen Company Information
13.10.2 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Fibrogen Main Business Overview
13.10.5 Fibrogen Latest Developments
13.11 Bristol-Myers Squibb
13.11.1 Bristol-Myers Squibb Company Information
13.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Bristol-Myers Squibb Main Business Overview
13.11.5 Bristol-Myers Squibb Latest Developments
13.12 Sarepta Therapeutics
13.12.1 Sarepta Therapeutics Company Information
13.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Sarepta Therapeutics Main Business Overview
13.12.5 Sarepta Therapeutics Latest Developments
13.13 GSK
13.13.1 GSK Company Information
13.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
13.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 GSK Main Business Overview
13.13.5 GSK Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Oculopharyngeal Muscular Dystrophy (OPMD) Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Tablets
Table 4. Major Players of Capsules
Table 5. Major Players of Injectable
Table 6. Major Players of Other
Table 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2022) & (K Units)
Table 8. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2022)
Table 9. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2022) & ($ million)
Table 10. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Type (2017-2022)
Table 11. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price By Type (2017-2022) & (US$/Unit)
Table 12. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2022)
Table 14. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2022)
Table 15. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Application (2017-2022)
Table 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price By Application (2017-2022) & (US$/Unit)
Table 17. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Company (2020-2022) & (K Units)
Table 18. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Company (2020-2022)
Table 19. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Company (2020-2022) ($ Millions)
Table 20. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Company (2020-2022)
Table 21. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sale Price by Company (2020-2022) & (US$/Unit)
Table 22. Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Producing Area Distribution and Sales Area
Table 23. Players Oculopharyngeal Muscular Dystrophy (OPMD) Products Offered
Table 24. Oculopharyngeal Muscular Dystrophy (OPMD) Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Geographic Region (2017-2022) & (K Units)
Table 28. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Geographic Region (2017-2022)
Table 29. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country/Region (2017-2022) & (K Units)
Table 32. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country/Region (2017-2022)
Table 33. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
Table 36. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2017-2022)
Table 37. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2017-2022)
Table 39. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2017-2022) & (K Units)
Table 40. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2022)
Table 41. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 42. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2022)
Table 43. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2017-2022) & (K Units)
Table 44. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2017-2022)
Table 45. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2017-2022)
Table 47. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2022) & (K Units)
Table 48. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2022)
Table 49. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 50. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2022)
Table 51. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
Table 52. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2017-2022)
Table 53. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2017-2022)
Table 55. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2017-2022) & (K Units)
Table 56. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2022)
Table 57. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 58. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2022)
Table 59. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
Table 60. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2022) & (K Units)
Table 64. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2022)
Table 65. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Application (2017-2022) & (K Units)
Table 66. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of Oculopharyngeal Muscular Dystrophy (OPMD)
Table 68. Key Market Challenges & Risks of Oculopharyngeal Muscular Dystrophy (OPMD)
Table 69. Key Industry Trends of Oculopharyngeal Muscular Dystrophy (OPMD)
Table 70. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Oculopharyngeal Muscular Dystrophy (OPMD) Distributors List
Table 73. Oculopharyngeal Muscular Dystrophy (OPMD) Customer List
Table 74. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Region (2023-2028) & (K Units)
Table 75. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Forecast by Region
Table 76. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Country (2023-2028) & (K Units)
Table 79. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Region (2023-2028) & (K Units)
Table 81. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast By Type (2023-2028) & (K Units)
Table 87. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Forecast By Type (2023-2028)
Table 88. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast By Type (2023-2028) & ($ Millions)
Table 89. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast By Type (2023-2028)
Table 90. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast By Application (2023-2028) & (K Units)
Table 91. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Forecast By Application (2023-2028)
Table 92. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast By Application (2023-2028) & ($ Millions)
Table 93. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast By Application (2023-2028)
Table 94. Benitec Biopharma Inc. Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 95. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 96. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 97. Benitec Biopharma Inc. Main Business
Table 98. Benitec Biopharma Inc. Latest Developments
Table 99. Bioblast Pharma Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 100. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 101. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 102. Bioblast Pharma Main Business
Table 103. Bioblast Pharma Latest Developments
Table 104. BioMarin Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 105. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 106. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 107. BioMarin Main Business
Table 108. BioMarin Latest Developments
Table 109. PTC Therapeutics Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 110. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 111. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 112. PTC Therapeutics Main Business
Table 113. PTC Therapeutics Latest Developments
Table 114. NS Pharma Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 115. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 116. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 117. NS Pharma Main Business
Table 118. NS Pharma Latest Developments
Table 119. Nobelpharma Co., Ltd Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 120. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 121. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 122. Nobelpharma Co., Ltd Main Business
Table 123. Nobelpharma Co., Ltd Latest Developments
Table 124. Santhera Pharmaceuticals Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 125. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 126. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 127. Santhera Pharmaceuticals Main Business
Table 128. Santhera Pharmaceuticals Latest Developments
Table 129. Pfizer Inc. Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 130. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 131. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 132. Pfizer Inc. Main Business
Table 133. Pfizer Inc. Latest Developments
Table 134. Marathon Pharmaceuticals Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 135. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 136. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 137. Marathon Pharmaceuticals Main Business
Table 138. Marathon Pharmaceuticals Latest Developments
Table 139. Fibrogen Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 140. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 141. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 142. Fibrogen Main Business
Table 143. Fibrogen Latest Developments
Table 144. Bristol-Myers Squibb Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 145. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 146. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 147. Bristol-Myers Squibb Main Business
Table 148. Bristol-Myers Squibb Latest Developments
Table 149. Sarepta Therapeutics Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 150. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 151. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 152. Sarepta Therapeutics Main Business
Table 153. Sarepta Therapeutics Latest Developments
Table 154. GSK Basic Information, Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Base, Sales Area and Its Competitors
Table 155. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Offered
Table 156. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 157. GSK Main Business
Table 158. GSK Latest Developments
List of Figures
Figure 1. Picture of Oculopharyngeal Muscular Dystrophy (OPMD)
Figure 2. Oculopharyngeal Muscular Dystrophy (OPMD) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Tablets
Figure 10. Product Picture of Capsules
Figure 11. Product Picture of Injectable
Figure 12. Product Picture of Other
Figure 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type in 2021
Figure 14. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Type (2017-2022)
Figure 15. Oculopharyngeal Muscular Dystrophy (OPMD) Consumed in Hospital Pharmacies
Figure 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market: Hospital Pharmacies (2017-2022) & (K Units)
Figure 17. Oculopharyngeal Muscular Dystrophy (OPMD) Consumed in Retail Pharmacies
Figure 18. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market: Retail Pharmacies (2017-2022) & (K Units)
Figure 19. Oculopharyngeal Muscular Dystrophy (OPMD) Consumed in Online Pharmacies
Figure 20. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market: Online Pharmacies (2017-2022) & (K Units)
Figure 21. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2022)
Figure 22. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Application in 2021
Figure 23. Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market by Company in 2021 ($ Million)
Figure 24. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Company in 2021
Figure 25. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Geographic Region in 2021
Figure 27. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2017-2022)
Figure 28. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country/Region in 2021
Figure 29. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2017-2022 (K Units)
Figure 30. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2017-2022 ($ Millions)
Figure 31. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2017-2022 (K Units)
Figure 32. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2017-2022 ($ Millions)
Figure 33. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2017-2022 (K Units)
Figure 34. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2017-2022 (K Units)
Figure 36. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2017-2022 ($ Millions)
Figure 37. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country in 2021
Figure 38. Americas Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country in 2021
Figure 39. United States Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region in 2021
Figure 44. APAC Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Regions in 2021
Figure 45. China Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 49. India Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country in 2021
Figure 52. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country in 2021
Figure 53. Germany Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 54. France Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy Oculopharyngeal Muscular Dy
Global Freckle-removing Medical and Beau..
The global market for Freckle-removing Medical and Beauty Eq..
+16467917070US (Toll Free)